DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Taliglucerase alfa
Taliglucerase alfa
List of Approved Ndas for Biological Products That Were Deemed to Be Blas on March 23, 2020
DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
AHFS Pharmacologic-Therapeutic Classification System
Enzyme Replacement Therapy Srx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment
Elelyso™ (Taliglucerase Alfa)
Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
Poster Session Abstracts
Annual Symposium of the Society for the Study of Inborn Errors of Metabolism Birmingham, UK, 4 – 7 September 2012
Culturas Celulares De Tabaco BY2 Para a Produção De Biofármacos: O Papel Da Metilação Do ADN Na Expressão Do Transgene
Safety and Immunogenicity of a Plant-Produced
Active Moiety Name FDA Established Pharmacologic Class (EPC) Text
Clinical Policy: Taliglucerase Alfa (Elelyso) Reference Number: CP.PHAR.157 Effective Date: 02/16 Coding Implications Last Review Date: 02/17 Revision Log
Tesis Egras Gaucher
Do Ultra-Orphan Medicinal Products Warrant Ultra-High Prices? a Review
A Rational Design Approach to Developing Second Generation Fabry Disease Treatments
May2013 CPG Updates
Lysosomal Storage Disorders Medical Drug Program Summary
Top View
Clinical Policy: Taliglucerase Alfa (Elelyso)
Cerezyme® (Imiglucerase), Elelyso® (Taliglucerase Alfa) and VPRIV® (Velaglucerase Alfa) Effective: April 13, 2021
ELELYSO Powder for Injection Is Packaged in a 13.5 Ml Type 1 Borosilicate Glass Vial
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Enzyme Replacement Therapy for Lysosomal Diseases: Lessons from 20 Years of Experience and Remaining Challenges
2; Potential Implications for the Pathogenesis of Gaucher and Parkinson's Diseases
Lysosomal Storage Diseases and Glycan Degradation
Introduction to FDA Review and Approval of Biological Products
5.01.576 Drugs for Rare Diseases
Alphabetical Listing by Therapeutic Category Dod UNIFORM
ELELYSO (Taliglucerase Alfa) RATIONALE for INCLUSION IN
Elelyso, INN-Taliglucerase Alfa
Product Monograph
Imiglucerase in the Treatment of Gaucher Disease: a History and Perspective
Lysosomal Storage Disease Overview
ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
Past Vs. Present New Generation of Specialty Management
Elelyso™ (Taliglucerase Alfa)
Current Specialty Pharmacy Drugs (As of July 1, 2021*) New Drugs Indicated in Red
Corporate Medical Policy
Elelyso® (Taliglucerase Alfa) VPRIV® (Velaglucerase Alfa)
New Brunswick Drug Plans Formulary
Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders
Mandatory Specialty Drug List
Phpprime Prior Auth Drug List
Wednesday, April 13, 2016 4 P.M
Appendix A: Medications Used in the Treatment of Inborn Errors
Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development
Applied Plant Genomics and Biotechnology Related Titles
AAA Atpases 55 ABC Chondroitin Lyases 74 Acarbose 517–518 2
Phase 1 Randomized Trial of a Plant-Derived Virus-Like Particle Vaccine for COVID-19
Abstract Book Table of Contents
Appendix A: Perioperative Medication Management
Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012
AHFS Pharmacologic-Therapeutic Classification System
Eliglustat (Genz 112638) As Inhibitor Of
“Deemed to Be a License” Provision of the Biologics Price Competition and Innovation Act of 2009
Annual Report 2010
Research Report 2013 UROLOGY Endocrinology
Poster Session Abstracts
Taliglucerase Alfa (Elelyso) Reference Number: ERX.SPMN.138 Effective Date: 10/16 Coding Implications Last Review Date: 09/16 Revision Log
ELELYSO (Taliglucerase Alfa) for Injection, for Intravenous Use with ELELYSO
Complement Inhibitor and Enzyme/Protein Replacement Therapy
(INN) for Biological and Biotechnological Substances
[Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
X Latin American Congress of Inborn Errors of Metabolism and Neonatal Screening
Anti-Taliglucerase Alpha Antibodies Associated with Lower Efficacy of ERT and Onset of Autoimmune Thyroiditis in a Patient With
Rôle Des Sphingolipides Dans La Cancérogenèse
L-Iduronidase in Maize for the Potential Treatment of a Human Lysosomal Storage Disease
Designated Medical Specialty Pharmacy Drug List
ELELYSO (Taliglucerase Alfa Rpc)
Aminocyclitol and Iminosugar Derivatives Related to Gauche Disease